Septic shock in humans: Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy

Annals of Internal Medicine

Volumn 113, Issue 3, 1990, Pages 227-242

  Parrillo, Joseph E ^a   Parker, Margaret M ^b   Natanson, Charles ^b   Suffredini, Anthony F ^b   Danner, Robert L ^b   Cunnion, Robert E ^b   Ognibene, Frederick P ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTISERUM; CORTICOSTEROID; DOPAMINE; ENDOTOXIN; HEART MUSCLE DEPRESSANT FACTOR; NALOXONE; NORADRENALIN; VASOACTIVE AGENT;

CARDIOVASCULAR FUNCTION; CONFERENCE PAPER; HEART OUTPUT; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; SEPTIC SHOCK; THEORETICAL STUDY;

ANIMAL; CARDIOVASCULAR SYSTEM; DOGS; ENDOTOXINS; HUMAN; SHOCK, SEPTIC; UNITED STATES;

EID: 0025303027     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-113-3-227     Document Type: Conference Paper

References (101)

1. Finland M. Changing ecology of bacterial infections as related to antibacterial therapy. J Infect Dis. 1970;122:419-31.
2. Wilson F. Surgical intensive care units. In: Parrillo JE, Ayres SM, eds. Major Issues in Critical Care Medicine. Baltimore: Williams & Wilkins; 1984:17-33.
3. Parrillo JE. Septic shock in humans: clinical evaluation, pathophysiology, and therapeutic approach. In: Shoemaker WC, Thompson WL, Holbrook P, et al, eds. Textbook of Critical Care. 2d ed. Philadelphia: Saunders; 1989:1006-23.
4. Parker MM, Parrillo JE. Septic shock. Hemodynamics and pathogenesis. JAMA. 1983;250:3324-7.
5. Parrillo JE. The cardiovascular response to human septic shock. In: Fuhrman BP, Shoemaker WC, eds. Critical Care: State of the Art. v. 10. Fullerton, California: Society of Critical Care Medicine; 1989:285-314.
6. McCabe WR, Kreger BE, Johns ME. Type-specific and cross-reactive antibodies in gram-negative bacteremia. N Engl J Med. 1972;287:261-7.
7. Wolff SM, Bennett JV. Gram-negative rod bacteremia [Editorial]. N Engl J Med. 1974;291:733-4.
8. Parker MM, Shelhamer JH, Natanson C, Alling DW, Parrillo JE. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit Care Med. 1987;15:923-9.
9. Braunwald E. Assessment of cardiac function. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia: Saunders; 1988:457.
10. Parker MM, Shelhamer JH, Bacharach SL, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med. 1984;100:483-90.
11. Parker MM, Suffredini AF, Natanson C, Ognibene FP, Shelhamer JH, Parrillo JE. Responses of left ventricular function in survivors and nonsurvivors of septic shock. J Crit Care. 1989;4:19-25.
12. Wilson RF, Thal AP, Kindling PH, et al. Hemodynamic measurements in septic shock. Arch Surg. 1965;91:121-9.
13. Winslow EJ, Loeb HS, Rahimtoola SH, Kamath S, Gunnar RM. Hemodynamic studies and results of therapy in 50 patients with bacteremic shock. Am J Med. 1973;54:421-32.
14. Weil MH, Shubin H, Biddle M. Shock caused by gram-negative microorganisms. Ann Intern Med. 1964;60:384-400.
15. Udhoji VN, Weil MH. Hemodynamic and metabolic studies on shock associated with bacteremia. Ann Intern Med. 1965;62:966-78.
16. Kwaan HM, Weil MH. Differences in the mechanism of shock caused by bacterial infections. Surg Gynecol Obstet. 1969;128: 37-45.
17. Ellrodt AG, Riedinger MS, Kimchi A, et al. Left ventricular performance in septic shock: reversible segmental and global abnormalities. Am Heart J. 1985;110:402-9.
18. Parker MM, McCarthy KE, Ognibene FP, Parrillo JE. Right ventricular dysfunction and dilatation, similar to left ventricular changes, characterize the cardiac depression of septic shock in humans. Chest. 1990;97:126-31.
19. Natanson C, Fink MP, Ballantyne HK, MacVittie TJ, Conklin JJ, Parrillo JE. Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock. J Clin Invest. 1986;78:259-70.
20. Weil MH, MacLean LH, Visscher MD, et al. Studies on the circulatory changes in the dog produced by endotoxin from gram-negative microorganisms. J Clin Invest. 1956;35:1191-8.
21. Hinshaw LB, Archer LL, Greenfield LJ, Guenter CA. Effects of endotoxin on myocardial hemodynamics, performance, and metabolism. Am J Physiol. 1971;221:504-10.
22. Natanson C, Danner RL, Fink MP, et al. Cardiovascular performance with Escherichia coli challenges in a canine model of human sepsis. Am J Physiol. 1988;254:H558-69.
23. Natanson C, Danner RL, Elin RJ, et al. The role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock. J Clin Invest. 1989;83:243-51.
24. Natanson C, Parrillo JE. Septic shock. In: Kuetom V, Askenasi J, eds. Anesthesiology Clinics of North America. v. 6. Philadelphia: Saunders; 1988:73-85.
25. Natanson C, Hoffman WD, Parrillo JE. Septic shock: the cardiovascular abnormality and therapy. J Cardiothoracic Anesthesia. 1989:3:215-27.
26. Natanson C, Eichenholz PW, Danner RL, et al. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med. 1989;169:823-32.
27. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330:662-4.
28. Natanson C, Eichacker PQ, Hoffman WD, et al. Human recombinant interleukin-1 produced minimal effects on canine cardiovascular function [Abstract]. Clin Res. 1989;37:346A.
29. Natanson C, Danner RL, Akin GL, et al. Antibiotics, fluids and dopamine in a lethal canine model of septic shock: effects on survival [Abstract]. Clin Res. 1988;36:372A.
30. Natanson C, Hoffman WD, Danner RL, et al. A controlled trial of plasmapheresis fails to improve outcome in an antibiotic treated canine model of human septic shock [Abstract]. Clin Res. 1989; 37:346A.
31. Wolff SM. Biological effects of bacterial endotoxins in man. J Infect Dis. 1973;128(Suppl):259-64.
32. Elin RJ, Wolff SM, McAdam KP, et al. Properties of reference Escherichia coli endotoxin and its phthalylated derivative in humans. J Infect Dis. 1981;144:329-36.
33. Carroll BJ, Pearson MJ, Martin FI. Evaluation of three acute tests of hypothalamic-pituitary-adrenal function. Metabolism. 1969;18: 476-83.
34. Bradley SE, Chasis H, Goldring W, Smith HW. Hemodynamic alterations in normotensive and hypertensive subjects during the pyrogenic reaction. J Clin Invest. 1945;24:749-58.
35. Athens JW, Haab OP, Raab SO, et al. Leukokinetic studies. IV: The total blood, circulating, and marginal granulocyte pools and the granulocyte turnover rate in normal subjects. J Clin Invest. 1961;40:989-95.
36. McDonald RK, Weise VK, Peterson RE. Effect of aspirin and reserpine on adrenocortical response to Piromen in man. Proc Soc Exp Biol Med. 1956;93:343-8.
37. Mechanic RC, Frei E, Landy M, et al. Quantitative studies of human leukocyte and febrile response to single and repeated doses of purified bacterial endotoxin. J Clin Invest. 1962;41:162-72.
38. Brues AM, Shear MJ. Chemical treatment of tumors. X. Reactions of four patients with advanced malignant tumors to injection of a polysaccharide from Serratia marcescens culture filtrate. J Nat Ca Inst. 1944;5:195-208.
39. Berry LJ. Introduction. In: Berry LJ, ed. Cellular Biology of Endotoxin. v. 3. Amsterdam: Elsevier; 1985:xvii-xxi.
40. Gilbert RM. Mechanisms of the hemodynamic effects of endotoxin. Physiol Rev. 1960;40:245-79.
41. Hochstein HD, Mills DF, Outschoorn AS, Rastogi SC. The processing and collaborative assay of reference endotoxin. J Biol Stand. 1983;11:251-60.
42. Dinarello CA. Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med. 1984;311:1413-8.
43. Moser KM, Perry RB, Luchsinger PC. Cardiopulmonary consequences of pyrogen-induced hyperexia in man. J Clin Invest. 1963; 42:626-34.
44. Suffredini AF, Fromm RE, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989;321:280-7.
45. Suffredini AF, Shelhamer JH, Neumann RD, et al. Intravenous endotoxin to normal humans causes gas exchange abnormalities and increased alveolar permeability [Abstract]. Clin Res. 1988; 36:511A.
46. Brigham K, Meyrick B. Endotoxin and lung injury. Am Rev Respir Dis. 1986;133:913-27.
47. Morrison DC, Ryan JL. Endotoxins and disease mechanisms. Annu Rev Med. 1987;38:417-32.
48. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987;316:379-85.
49. Hesse DG, Tracey KJ, Fong Y, et al. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet. 1988;166:147-53.
50. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988;318:1481-6.
51. Revhaug A, Michie HR, Manson JM, et al. Inhibition of cyclooxygenase attenuates the metabolic response to endotoxin in humans. Arch Surg. 1988;123:162-70.
52. Fromm RE, Suffredini AF, Kovacs JA, Schlesinger T, Parrillo JE. Serum tumor necrosis factor response in humans receiving endotoxin [Abstract]. Clin Res. 1988;36:372A.
53. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med. 1989;320: 1165-72.
54. Danner RL, Suffredini AF, Natanson C, Parrillo JE. Microbial toxins: role in the pathogenesis of septic shock and multiple organ failure. In: Cerra FB, Bihari DE, eds. New Horizons: Multiple Organ Failure. Fullerton, California: Society of Critical Care Medicine; 1989:151-91.
55. Shenep JL, Morgan KA. Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis. J Infect Dis. 1984;150:380-8.
56. Tracey KJ, Lowry SF, Cerami A. Cachectin: a hormone that triggers acute shock and chronic cachexia. J Infect Dis. 1988;157: 413-20.
57. Beutler B, Milsaark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from the lethal effects of endotoxin. Science. 1981;229:869-71.
58. Nedwin GE, Svedersky LP, Bringman TS, Palladino MA Jr, Goeddel DV. Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta. J Immunol. 1985;135:2492-7.
59. Jupin C, Anderson S, Damais C, Alouf JE, Parant M. Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factors and gamma interferon. J Exp Med. 1988;167:752-61.
60. Sun XM, Hsueh W. Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor. J Clin Invest. 1988;81:1328-31.
61. Wang J, Dunn MJ. Platelet-activating factor mediates endotoxin-induced acute renal insufficiency in rats. Am J Physiol. 1987; 253:F1283-9.
62. Ziegler EJ. Protective antibody to endotoxin core: the emperor's new clothes? J Infect Dis. 1988;158:286-90.
63. McCabe WR, Kreger BE, Johns M. Type-specific and cross-reactive antibodies in gram-negative bacteremia. N Engl J Med. 1972; 287:261-7.
64. Ziegler EJ, McCutchan JA, Fierer J, et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med. 1982;307:1225-30.
65. McCabe WR, Olans RW. Shock in gram-negative bacteremia: predisposing factors, pathophysiology, and treatment. In: Remington JS, Swartz MN, eds. Current Clinical Topics in Infectious Diseases. v. 2. New York: McGraw-Hill; 1981:121-50.
66. Greisman SE, Hornick RB, Wagner HN Jr, Woodward WE, Woodward TE. The role of endotoxin during typhoid fever and tularemia in man. IV. The integrity of the endotoxin tolerance mechanisms during infection. J Clin Invest. 1969;48:613-29.
67. Elin RJ, Robinson RA, Levine AS, Wolff SM. Lack of clinical usefulness of the limulus test in the diagnosis of endotoxemia. N Engl J Med. 1975;293:521-4.
68. Danner RL, Elin RJ, Hoseini JM, et al. Endotoxin determinations in 100 patients with septic shock [Abstract]. Clin Res. 1988;36: 453A.
69. Rifkind D. Prevention by polymyxin B of endotoxin lethality in mice. J Bacteriol. 1967;93:1463-4.
70. Fromm AL, Fong JS, Good RA. Polymyxin B sulfate modification of bacterial endotoxin: efiects on the development of endotoxin shock in dogs. Infect Immun. 1979;23:660-4.
71. Greisman SE, Johnston CA. Failure of antisera to J5 and R595 rough mutants to reduce endotoxemic lethality. J Infect Dis. 1988; 157:54-64.
72. Proctor RA, Will JA, Burhop KE, Raetz CR. Protection of mice against lethal endotoxemia by a lipid A precursor. Infect Immun. 1986;52:905-7.
73. Golenbock DT, Will JA, Raetz CR, Proctor RA. Lipid X ameliorates pulmonary hypertension and protects sheep from death due to endotoxin. Infect Immun. 1987;55:2471-6.
74. Danner RL, Joiner KA, Parrillo JE. Inhibition of endotoxin-induced priming of human neutrophils by lipid X and 3-Aza-lipid X. J Clin Invest. 1987;80:605-12.
75. Cunnion RE, Parrillo JE. Myocardial dysfunction in sepsis. Crit Care Clin. 1989;5:99-118.
76. Adiseshiah M, Baird RJ. Correlation of the changes in diastolic myocardial tissue pressure and regional coronary blood flow in hemorrhagic and endotoxic shock. J Surg Res. 1978;24:20-5.
77. Hinshaw LB, Archer LT, Spitzer JJ, Black MR, Peyton MD, Gretnfield LJ. Effect of coronary hypotension and endotoxin on myocardial performance. Am J Physiol. 1974;227:1051-7.
78. Lefer AM, Martin J. Origin of myocardial depressant factor in shock. Am J Physiol. 1970;218:1423-7.
79. Carli A, Auclair MC, Benassayag C, Nunez E. Evidence for an early lipid soluble cardiodepressant factor in rat serum after a sublethal dose of endotoxin. Circ Shock. 1981;8:301-12.
80. Greene LJ, Shapanka R, Glenn TM, Lefer AM. Isolation of myocardial depressant factor from plasma of dogs in hemorrhagic shock. Biochem Biophys Acta. 1977;491:275-85.
81. Cunnion RE, Schaer GL, Parker MM, Natanson C, Parrillo JE. The coronary circulation in human septic shock. Circulation. 1986; 73:637-44.
82. Dhainaut JF, Huyghebaert MF, Monsallier JF, et al. Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. Circulation. 1987;75:533-41.
83. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W. A circulating myocardial depressant substance in humans with septic shock. J Clin Invest. 1985;76:1539-53.
84. Schuette WH, Burch C, Roach PO, Parrillo JE. Closed loop television tracking of beating heart cells in vitro. Cytometry. 1987; 8:101-3.
85. Reilly JM, Cunnion RE, Burch-Whitman C, Parker MM, Shelhamer JH, Parrillo JE. A circulating myocardial depressant substance is associated with cardiac dysfunction and peripheral hypoperfusion (lactic acidemia) in patients with septic shock. Chest. 1989;95: 1072-80.
86. Hollenberg SM, Cunnion RE, Lawrence M, Kelley JL, Parrillo JE. Tumor necrosis factor depresses myocardial cell function: results using an in vitro assay of myocyte performance [Abstract]. Clin Res. 1989;37:528A.
87. Li TC, Phillips MC, Shaw L, Cook EF, Natanson C, Goldman L. Onsite physician staffing in a community hospital intensive care unit. Impact on test and procedure use and on patient outcome. JAMA. 1984;252:2023-7.
88. Reynolds HN, Haupt MT, Thill-Baharozian MC, Carlson RW. Impact of critical care physician staffing on patients with septic shock in a university hospital medical intensive care unit. JAMA. 1988; 260:3446-50.
89. Kaplan RL, Sahn SA, Petty TL. Incidence and outcome of the respiratory distress syndrome in gram-negative sepsis. Arch Intern Med. 1979;139:867-9.
90. Fein AM, Lippman M, Holzman H, Eliraz A, Goldberg SK. The risk factors, incidence, and prognosis of ARDS following septicemia. Chest. 1983;83:40-2.
91. Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med. 1980;68:344-55.
92. Bryan CS, Reynolds KL, Brenner ER. Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis. 1983;5:629-38.
93. Ognibene FP, Parker MM, Natanson C, Shelhamer JH, Parrillo JE. Depressed left ventricular performance. Response to volume infusion in patients with sepsis and septic shock. Chest. 1988;93: 903-10.
94. Schaer GL, Fink MP, Parrillo JE. Norepinephrine alone versus norepinephine plus low-dose dopamine: enhanced renal blood flow with combination pressor therapy. Crit Care Med. 1985;13:492-6.
95. Desjars P, Pinaud M, Potel G, Tasseau F, Touze MD. A reappraisal of norepinephrine therapy in human septic shock. Crit Care Med. 1987;15:134-7.
96. Meadows D, Edwards D, Wilkins RG, Nightingale P. Reversal of intractable septic shock with norepinephrine therapy. Crit Care Med. 1988;16:663-6.
97. Sprung CL, Caralis PV, Marcial E, et al. The effects of high-dose corticosteroids in patients with septic shock: a prospective, controlled study. N Engl J Med. 1984;311:1137-43.
98. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653-8.
99. Hinshaw L, Peduzzi P, Young E, et al. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The Veterans Administration Systemic Sepsis Cooperative Study Group. N Engl J Med. 1987;317:659-65.
100. Parker MM, Parrillo JE. Septic shock and other forms of distributive shock. In: Parrillo JE, ed. Current Therapy in Critical Care Medicine. Philadelphia: B.C. Decker; 1987:44-55.
101. Jacobs R, Kaliner M, Shelhamer JH, Parrillo JE. Blood histamine concentrations are not elevated in humans with septic shock. Crit Care Med. 1989;17:30-5.